An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Immunotherapy Regenerative Medicine Clinic on Using Stem Cells to Activate the Body's Natural Healing Poweron April 18, 2024 at 10:02 am
Stem cell therapy, a cornerstone of regenerative medicine, has shown immense potential in treating autoimmune diseases, aging conditions, and
- Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinicon April 18, 2024 at 4:00 am
Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced that the company has raised $25 million in the first close of a Series B financing.
via Bing News